Finance

Beta
Lists
QDEL:NASDAQ
Quidelortho Corp
$12.39
+4.03%
(+0.48) 1D
$12.45
+0.48% (+0.060)
After hours
Closed: May 21, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for QDEL...
Open
$11.69
High
$12.50
Low
$11.42
Mkt. cap
844.89M
Avg. vol.
2.86M
Volume
1.86M
52-wk high
$35.58
52-wk low
$9.92
EPS
-$17.82
Beta
0.75
Shares outstanding
68.19M
No. of employees
6K
News stories
From sources across the web
Profile
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide. On May 8, 2020 the U.S. Food and Drug Administration issued to Quidel the first emergency use authorization for a COVID-19 rapid antigen test, a new category of tests for use in the ongoing pandemic. These diagnostic tests quickly detect fragments of proteins found on or within the virus by testing samples collected from the nasal cavity using swabs. Wikipedia
About Quidelortho Corp
CEODouglas C Bryant
Employees6.5K
Founded1979
HeadquartersSan Diego, California, United States
SectorMedical device
Websitequidelortho.com
Last report
May 5, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.04 / $0.36
-111.21%miss
Revenue / Est. (USD)
619.80M / 659.18M
-5.97%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
613.90M
699.90M
723.60M
619.80M
Cost of goods sold
339.00M
362.80M
401.90M
354.00M
Cost of revenue
339.00M
362.80M
401.90M
354.00M
Research and development expenses
45.70M
41.50M
45.80M
44.90M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
178.00M
186.90M
194.40M
199.30M
Operating expense
279.40M
290.40M
292.70M
291.20M
Total operating expenses
618.40M
653.20M
694.60M
645.20M
Operating income
-4.50M
46.70M
29.00M
-25.40M
Other non operating income
-5.90M
-1.20M
3.60M
-2.00M
EBT including unusual items
-229.60M
-756.90M
-112.40M
-79.50M
EBT excluding unusual items
-53.40M
-300.00K
-17.10M
-73.10M
Income tax expense
25.80M
-23.90M
18.30M
12.30M
Effective tax rate
-11.24%
3.16%
-16.28%
-15.47%
Other operating expenses
5.10M
14.30M
6.90M
200.00K
Net income
-255.40M
-733.00M
-130.70M
-91.80M
Net profit margin
-41.60%
-104.73%
-18.06%
-14.81%
Earnings per share
0.12
0.80
0.46
-0.04
Interest and investment income
600.00K
500.00K
500.00K
900.00K
Interest expense
-43.60M
-49.10M
-52.00M
-49.00M
Net interest expenses
-43.00M
-48.60M
-51.50M
-48.10M
Depreciation and amortization charges
-
-
-
-
EBITDA
105.80M
158.80M
137.90M
85.50M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer